ClinicalTrials.gg
CompletedNCT02061761Updated Mar 24, 2023Results posted

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

A Phase 1/2 interventional study of BMS-986016 and BMS-936558 in Hematologic Neoplasms, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Hematologic Neoplasms · Bristol-Myers Squibb.

Enrollment
3rd of 13
106 · median 60
Started
2014
with 1 other
Phase 1/2
3 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2014, is one of 3 in phase 1/2, and was the 11th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

None of the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb is open now. The open studies under Hematologic Neoplasms, anywhere →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Hematologic Neoplasms by Bristol-Myers Squibb as a file.
02

Study summary

The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with relapsed or refractory B-cell malignancies. Co-primary objective is to investigate the preliminary efficacy of relatlimab in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffused Large B Cell lymphoma (DLBCL)

03

Conditions studied

  • Hematologic Neoplasms

Keywords

  • Hodgkin lymphoma
  • non-Hodgkin lymphoma
  • diffused large B-cell lymphoma
  • indolent lymphoma
  • chronic lymphocytic leukemia
  • relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have histologic or cytologic confirmation of chronic lymphocytic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, or Multiple Myeloma and have following prior treatment or been refractory to prior treatment
  • Must have progressed or been refractory to, at least one prior standard therapy, including radiation, immunomodulatory agents (eg, lenalidomide), immunotherapy, cytotoxic chemotherapy, and select antibody (anti-CD20, alemtuzumab, or anti-CD30) therapy.
  • Must be more than 100 days post transplant

Exclusion criteria

Exclusion Criteria:

  • Known or suspected central nervous system (CNS) or with the CNS as the only site of active disease (controlled are allowed)
  • Known or suspected disease
  • History of allergy to or anti-PD-L1 antibody therapy or to other monoclonal antibodies or related compounds or to any of their components

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Part A - relatlimab (Dose escalation)

    Biological: BMS-986016

  • Experimental
    Part C - relatlimab + nivolumab (Dose escalation)

    Biological: BMS-986016 · Biological: BMS-936558

  • Experimental
    Part B - relatlimab (Cohort expansion)

    Biological: BMS-986016

  • Experimental
    Part D - relatlimab + nivolumab (Cohort expansion)

    Biological: BMS-986016 · Biological: BMS-936558

Interventions

  • BiologicalBMS-986016

    Specified Dose on Specified Days

    Also known as: Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), relatlimab

  • BiologicalBMS-936558

    Specified Dose on Specified Days

    Also known as: Anti-PD-1 (Anti-Programmed-Death-1), MDX-1106, nivolumab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    Number of participants with any grade adverse events (AEs), any grade serious adverse events (SAEs) and any grade AEs leading to discontinuation of any drug. The severity of AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days post last dose (Up to 51 months)

  2. Number of Participants Who Died

    Number of participants who died due to any cause.

    Time frame: From first dose to 135 days post last dose (Up to 52 months)

  3. Number of Participants With On-Treatment Laboratory Abnormalities in Specific Hepatics Tests

    Number of participants with laboratory abnormalities in specific hepatic tests based on SI unit convention. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN

    Time frame: From first dose to 30 days post last dose (Up to 49 months)

  4. Objective Response Rate (ORR) - Part D

    Investigator-assessed ORR per International Working Group (IWG 2007) response criteria for malignant lymphoma is defined as the number of participants with a best overall documented response (BOR) of either a complete response (CR) or partial response (PR). Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.

    Time frame: From first dose date to the date of disease progression per investigator or the date of subsequent therapy, whichever occurs first (Up to approximately 95 months)

  5. Duration of Response (DoR) - Part D

    Investigator-assessed DoR per International Working Group (IWG 2007)) response criteria for malignant lymphoma is defined as the time between the date of first documented response (complete response or partial response) to the date of the first objectively documented progression, or death due to any cause, whichever occurs first. Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.

    Time frame: From first dose to the date of the first objectively documented progression, or death due to any cause, whichever occurs first (Up to approximately 95 months)

Secondary outcomes

  1. BMS-986016 Maximum Observed Serum Concentration (Cmax)

    BMS-986016 Maximum Observed Serum Concentration (Cmax). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  2. BMS-986016 Time of Maximum Observed Serum Concentration (Tmax)

    BMS-986016 Time of Maximum Observed Serum Concentration (Tmax). Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  3. BMS-986016 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU))

    BMS-986016 Area under the concentration-time curve in one dosing interval (AUC(TAU)). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  4. BMS-986016 Concentration at the End of a Dosing Interval (Ctau)

    BMS-986016 Concentration at the end of a dosing interval (Ctau). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  5. BMS-986016 Effective Elimination Half-life That Explains the Degree of AUC Accumulation Observed (T 1/2eff AUC)

    BMS-986016 effective elimination half-life that explains the degree of AUC accumulation observed (t 1/2eff AUC). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  6. BMS-986016 Total Body Clearance (CL/T)

    BMS-986016 total body clearance (CL/T). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  7. BMS-986016 Cmax Accumulation Index (AI_Cmax)

    BMS-986016 cmax accumulation index (AI_Cmax). AI is calculated based on ratio of Cmax at steady state to Cmax after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  8. BMS-986016 Accumulation Index (AI_AUC)

    BMS-986016 accumulation index (AI_AUC). AI is calculated based on ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  9. BMS-986016 Ctau Accumulation Index (AI_Ctau)

    BMS-986016 Ctau accumulation index (AI_Ctau). AI is calculated based on ratio of Ctau at steady state to Ctau after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  10. BMS-986016 Average Concentration Over a Dosing Interval ([AUC(TAU)/Tau] (Css,Avg)

    BMS-986016 average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css,avg). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1

  11. BMS-986016 Trough Observed Serum Concentration (Ctrough)

    BMS-986016 trough observed serum concentration (Ctrough). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

    Time frame: PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 15, 29, 43, Cycle 2 Day 1, 15, 29, Cycle 3 Day 1, 15, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, and Cycle 11 Day 1

  12. Number of Participants With Anti-BMS-986016 Antibodies (ADA)

    Number of participants with anti-BMS-986016 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.

    Time frame: From first dose to 135 days post last dose (Up to 52 months)

  13. Number of Participants With Anti-Nivolumab Antibodies (ADA)

    Number of participants with anti-Nivolumab antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.

    Time frame: From first dose to 135 days post last dose (Up to 52 months)

07

Results

Posted Mar 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 240mg Part BBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + NivolumabBMS-986016 160mg + Nivolumab Part D
Started39691171456
Chronic lymphocytic leukemia (cll)000020000
Diffuse large b-cell lymphoma (dlbcl)0000200015
Indolent non-hodgkin lymphoma (inhl)000040000
Hodgkin lymphoma (hl)000030000
Hl-anti-pd-1 naive0000000021
Hl-anti-pd-1 progressed0000000020
Completed010002005
Not completed38691151451
Withdrew: Disease progression2845931228
Withdrew: Study drug toxicity000001026
Withdrew: Adverse event unrelated to study drug100100000
Withdrew: Participant request to discontinue study treatment002201002
Withdrew: Withdrawal by subject000000002
Withdrew: Maximum clinical benefit000100006
Withdrew: Participant no longer meets study criteria000000001
Withdrew: Other reasons000020006

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

Number of participants with any grade adverse events (AEs), any grade serious adverse events (SAEs) and any grade AEs leading to discontinuation of any drug. The severity of AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days post last dose (Up to 51 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
ParticipantsBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
AEs395197159
SAEs14264026
AEs leading to discontinuation1201109
PrimaryNumber of Participants Who Died

Number of participants who died due to any cause.

Time frame:
From first dose to 135 days post last dose (Up to 52 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Number of Participants Who Died02122010
PrimaryNumber of Participants With On-Treatment Laboratory Abnormalities in Specific Hepatics Tests

Number of participants with laboratory abnormalities in specific hepatic tests based on SI unit convention. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN

Time frame:
From first dose to 30 days post last dose (Up to 49 months)
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Laboratory Abnormalities in Specific Hepatics Tests
ParticipantsBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
ALT OR AST > 3XULN0000005
ALT OR AST > 5XULN0000001
ALT OR AST > 10XULN0000001
ALT OR AST > 20XULN0000001
TOTAL BILIRUBIN > 2XULN0001001
ALP > 1.5XULN1101108
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY0000002
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS0000002
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY0000001
CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS0000001
PrimaryObjective Response Rate (ORR) - Part D

Investigator-assessed ORR per International Working Group (IWG 2007) response criteria for malignant lymphoma is defined as the number of participants with a best overall documented response (BOR) of either a complete response (CR) or partial response (PR). Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.

Time frame:
From first dose date to the date of disease progression per investigator or the date of subsequent therapy, whichever occurs first (Up to approximately 95 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) - Part D
Percentage of participantsHL Naive BMS-986016 160mg + NivolumabDLBCL BMS-986016 160mg + NivolumabHL Post I/O BMS-986016 160mg + Nivolumab
Objective Response Rate (ORR) - Part D61.9 (38.4 to 81.9)6.7 (0.2 to 31.9)15.0 (3.2 to 37.9)
PrimaryDuration of Response (DoR) - Part D

Investigator-assessed DoR per International Working Group (IWG 2007)) response criteria for malignant lymphoma is defined as the time between the date of first documented response (complete response or partial response) to the date of the first objectively documented progression, or death due to any cause, whichever occurs first. Complete response: Disappearance of all evidence of disease. Partial response: Regression of measurable disease and no new sites. \>= 50% decrease in sum of the produce of the diameters of up to 6 largest dominant masses (index lesions); no increase in size of other nodes (non-index lesions). Progressive disease: Any new lesion or increase by \>=50% of previously involved sites from nadir.

Time frame:
From first dose to the date of the first objectively documented progression, or death due to any cause, whichever occurs first (Up to approximately 95 months)
Reported as:
Median · Months
Duration of Response (DoR) - Part D
MonthsHL Naive BMS-986016 160mg + NivolumabDLBCL BMS-986016 160mg + NivolumabHL Post I/O BMS-986016 160mg + Nivolumab
Duration of Response (DoR) - Part D14.16 (2.56 to NA)NA (NA to NA)6.37 (1.84 to NA)
SecondaryBMS-986016 Maximum Observed Serum Concentration (Cmax)

BMS-986016 Maximum Observed Serum Concentration (Cmax). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · ug/mL
BMS-986016 Maximum Observed Serum Concentration (Cmax)
ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Period 0, Cycle 1, Day 1 (P0C1D1)3.697 ± NA22.738 ± NA224.802 ± NA68.718 ± NA19.990 ± NA57.900 ± NA40.402 ± NA
P0C3D16.660 ± NA31.917 ± NA673.000 ± NA116.419 ± NA44.532 ± NA149.000 ± NA88.196 ± NA
P1C1D1—————59.600 ± NA68.400 ± NA
P1C3D1—————165.000 ± NA163.000 ± NA
SecondaryBMS-986016 Time of Maximum Observed Serum Concentration (Tmax)

BMS-986016 Time of Maximum Observed Serum Concentration (Tmax). Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Median · Hours
BMS-986016 Time of Maximum Observed Serum Concentration (Tmax)
HoursBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Period 0, Cycle 1, Day 1 (P0C1D1)0.97 (0.97 to 0.97)1.300 (1.00 to 4.00)4.167 (1.00 to 24.00)1.825 (0.97 to 95.75)3.950 (1.00 to 5.00)0.97 (0.97 to 0.97)1.600 (0.97 to 24.07)
P0C3D10.984 (0.97 to 1.00)10.975 (1.37 to 20.58)168.22 (168.22 to 168.22)1.233 (0.97 to 23.87)1.017 (1.00 to 4.00)1.000 (1.00 to 1.00)3.467 (0.92 to 46.45)
P1C1D1—————4.000 (4.00 to 4.00)1.750 (1.75 to 1.75)
P1C3D1—————24.000 (24.00 to 24.00)0.900 (0.90 to 0.90)
SecondaryBMS-986016 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU))

BMS-986016 Area under the concentration-time curve in one dosing interval (AUC(TAU)). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · h*ug/mL
BMS-986016 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU))
h*ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Period 0, Cycle 1, Day 1 (P0C1D1)401.438 ± NA2852.533 ± NA44296.525 ± NA9086.827 ± NA2908.011 ± NA9480.758 ± NA5327.954 ± NA
P0C3D1712.408 ± NA4898.034 ± NA176405.369 ± NA18783.970 ± NA6166.165 ± NA34573.957 ± NA20464.075 ± NA
P1C1D1—————11259.871 ± NA11433.253 ± NA
P1C3D1—————38472.003 ± NA33919.259 ± NA
SecondaryBMS-986016 Concentration at the End of a Dosing Interval (Ctau)

BMS-986016 Concentration at the end of a dosing interval (Ctau). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · h*ug/mL
BMS-986016 Concentration at the End of a Dosing Interval (Ctau)
h*ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Period 0, Cycle 1, Day 1 (P0C1D1)0.158 ± NA1.037 ± NA75.589 ± NA12.221 ± NA3.848 ± NA19.500 ± NA8.417 ± NA
P0C3D10.256 ± NA2.266 ± NA293.000 ± NA30.970 ± NA9.556 ± NA103.000 ± NA47.016 ± NA
P1C1D1—————25.900 ± NA24.200 ± NA
P1C3D1—————86.600 ± NA86.100 ± NA
SecondaryBMS-986016 Effective Elimination Half-life That Explains the Degree of AUC Accumulation Observed (T 1/2eff AUC)

BMS-986016 effective elimination half-life that explains the degree of AUC accumulation observed (t 1/2eff AUC). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Mean · Hours
BMS-986016 Effective Elimination Half-life That Explains the Degree of AUC Accumulation Observed (T 1/2eff AUC)
HoursBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D1240.671 ± 143.5338742.843 ± NA547.986 ± NA428.698 ± 346.4046548.741 ± 78.0213720.317 ± NA674.755 ± 296.9473
P1C3D1—————638.597 ± NA524.637 ± NA
SecondaryBMS-986016 Total Body Clearance (CL/T)

BMS-986016 total body clearance (CL/T). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 = Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · mL/h
BMS-986016 Total Body Clearance (CL/T)
mL/hBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D128.074 ± NA16.333 ± NA4.535 ± NA12.777 ± NA12.974 ± NA6.942 ± NA7.819 ± NA
P1C3D1—————6.238 ± NA4.717 ± NA
SecondaryBMS-986016 Cmax Accumulation Index (AI_Cmax)

BMS-986016 cmax accumulation index (AI_Cmax). AI is calculated based on ratio of Cmax at steady state to Cmax after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · ug/mL
BMS-986016 Cmax Accumulation Index (AI_Cmax)
ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D11.981 ± NA1.701 ± NA2.009 ± NA1.734 ± NA2.369 ± NA2.573 ± NA2.139 ± NA
P1C3D1—————2.768 ± NA2.383 ± NA
SecondaryBMS-986016 Accumulation Index (AI_AUC)

BMS-986016 accumulation index (AI_AUC). AI is calculated based on ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · Ratio
BMS-986016 Accumulation Index (AI_AUC)
RatioBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D11.577 ± NA1.850 ± NA2.894 ± NA2.186 ± NA2.017 ± NA3.647 ± NA3.268 ± NA
P1C3D1—————3.417 ± NA2.967 ± NA
SecondaryBMS-986016 Ctau Accumulation Index (AI_Ctau)

BMS-986016 Ctau accumulation index (AI_Ctau). AI is calculated based on ratio of Ctau at steady state to Ctau after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · Ratio
BMS-986016 Ctau Accumulation Index (AI_Ctau)
RatioBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D10.743 ± NA2.494 ± NA4.741 ± NA2.310 ± NA1.686 ± NA5.282 ± NA4.162 ± NA
P1C3D1—————3.344 ± NA3.558 ± NA
SecondaryBMS-986016 Average Concentration Over a Dosing Interval ([AUC(TAU)/Tau] (Css,Avg)

BMS-986016 average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css,avg). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 1, Cycle 3 Day 1
Reported as:
Geometric mean · ug/mL
BMS-986016 Average Concentration Over a Dosing Interval ([AUC(TAU)/Tau] (Css,Avg)
ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C3D12.117 ± NA14.738 ± NA526.269 ± NA57.790 ± NA18.345 ± NA103.805 ± NA61.385 ± NA
P1C3D1—————120.595 ± NA109.013 ± NA
SecondaryBMS-986016 Trough Observed Serum Concentration (Ctrough)

BMS-986016 trough observed serum concentration (Ctrough). Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. Period 0 = treatment period Period 1 - Re-challenge period

Time frame:
PK assessment include the following timepoints: pre-dose, 1, 4, 24, 48, 96, 144, 192 hours end-of-infusion on cycle 1 Day 15, 29, 43, Cycle 2 Day 1, 15, 29, Cycle 3 Day 1, 15, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, and Cycle 11 Day 1
Reported as:
Geometric mean · ug/mL
BMS-986016 Trough Observed Serum Concentration (Ctrough)
ug/mLBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
P0C1D150.064 ± NA1.457 ± NA75.589 ± NA12.221 ± NA3.848 ± NA19.500 ± NA10.609 ± NA
P0C1D290.088 ± NA4.324 ± NA155.896 ± NA20.982 ± NA13.066 ± NA32.400 ± NA18.221 ± NA
P0C1D43————9.435 ± NA44.700 ± NA25.234 ± NA
P0C2D10.777 ± NA6.609 ± NA298.666 ± NA37.013 ± NA9.389 ± NA59.000 ± NA28.428 ± NA
P0C2D15————6.209 ± NA62.000 ± NA30.218 ± NA
P0C2D29——289.000 ± NA—26.700 ± NA70.900 ± NA36.675 ± NA
P0C3D11.020 ± NA19.018 ± NA313.000 ± NA16.648 ± NA6.867 ± NA93.300 ± NA45.535 ± NA
P0C3D150.256 ± NA2.266 ± NA293.000 ± NA9.450 ± NA9.556 ± NA103.000 ± NA45.685 ± NA
P0C5D10.729 ± NA1.917 ± NA—18.198 ± NA23.381 ± NA149.000 ± NA57.068 ± NA
P0C7D1—59.600 ± NA—5.760 ± NA20.264 ± NA143.000 ± NA58.408 ± NA
P0C9D1—62.000 ± NA—5.860 ± NA22.800 ± NA117.000 ± NA56.054 ± NA
P0C11D1—48.100 ± NA—4.710 ± NA31.200 ± NA165.000 ± NA67.268 ± NA
P1C1D15—————25.900 ± NA24.200 ± NA
P1C1D29—————43.600 ± NA41.000 ± NA
P1C1D43—————61.800 ± NA56.000 ± NA
P1C2D1—————73.800 ± NA58.700 ± NA
P1C2D15—————84.700 ± NA69.400 ± NA
P1C2D29—————81.500 ± NA71.900 ± NA
P1C3D1—————94.600 ± NA85.500 ± NA
P1C3D15—————86.600 ± NA86.100 ± NA
P1C5D1—————109.000 ± NA70.100 ± NA
P1C7D1—————107.000 ± NA105.000 ± NA
P1C9D1—————115.000 ± NA110.000 ± NA
P1C11D1——————115.000 ± NA
SecondaryNumber of Participants With Anti-BMS-986016 Antibodies (ADA)

Number of participants with anti-BMS-986016 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.

Time frame:
From first dose to 135 days post last dose (Up to 52 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-BMS-986016 Antibodies (ADA)
ParticipantsBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Baseline ADA Positive0116005
ADA Positive0007304
ADA Negative375124148
SecondaryNumber of Participants With Anti-Nivolumab Antibodies (ADA)

Number of participants with anti-Nivolumab antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is defined as a participant with positive seroconversion detected in the last sample before initiation of treatment. ADA-positive participant is a participant with at least one ADA-positive sample relative to baseline after initiation of the treatment. ADA negative participant is defined as a participant with no ADA positive sample after the initiation of treatment.

Time frame:
From first dose to 135 days post last dose (Up to 52 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Nivolumab Antibodies (ADA)
ParticipantsBMS-986016 20mgBMS-986016 80mgBMS-986016 800mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + Nivolumab
Baseline ADA Positive————000
ADA Positive————001
ADA Negative————4145

Adverse events

Collected over Serious Adverse Events (SAEs) and Other (Not including Serious) Adverse Events (AEs) are collected from first dose to 135 days post last dose (Up to 52 months). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 95 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Mono Esc 20 Q2W2/3 (66.7%)1/3 (33.3%)3/3 (100%)
All Mono Esc 80 Q2W3/9 (33.3%)5/9 (55.6%)9/9 (100%)
All Mono Esc 240 Q2W0/9 (0%)1/9 (11.1%)8/9 (88.9%)
All Mono Esc 800 Q2W1/6 (16.7%)2/6 (33.3%)5/6 (83.3%)
CLL BMS-986016 240mg1/2 (50%)1/2 (50%)2/2 (100%)
DLBCL BMS-986016 240mg2/2 (100%)2/2 (100%)2/2 (100%)
iNHL BMS-986016 240mg0/4 (0%)2/4 (50%)4/4 (100%)
HL BMS-986016 240mg0/3 (0%)1/3 (33.3%)3/3 (100%)
All Combo Esc 80/240 Q2W5/7 (71.4%)4/7 (57.1%)7/7 (100%)
All Combo Esc 160/240 Q2W2/4 (50%)2/4 (50%)4/4 (100%)
All Combo Esc 240/240 Q2W0/1 (0%)0/1 (0%)1/1 (100%)
HL Naive BMS-986016 160mg + Nivolumab1/21 (4.8%)6/21 (28.6%)20/21 (95.2%)
DLBCL BMS-986016 160mg + Nivolumab13/15 (86.7%)11/15 (73.3%)11/15 (73.3%)
HL Post I/O BMS-986016 160mg + Nivolumab3/20 (15%)9/20 (45%)20/20 (100%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventAll Mono Esc 20 Q2WAll Mono Esc 80 Q2WAll Mono Esc 240 Q2WAll Mono Esc 800 Q2WCLL BMS-986016 240mgDLBCL BMS-986016 240mgiNHL BMS-986016 240mgHL BMS-986016 240mgAll Combo Esc 80/240 Q2WAll Combo Esc 160/240 Q2WAll Combo Esc 240/240 Q2WHL Naive BMS-986016 160mg + NivolumabDLBCL BMS-986016 160mg + NivolumabHL Post I/O BMS-986016 160mg + Nivolumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/33/90/91/60/22/20/40/32/70/40/11/219/150/20
AnaemiaBlood and lymphatic system disorders0/30/90/90/60/21/20/40/30/70/40/10/210/150/20
Blood thyroid stimulating hormone increasedInvestigations0/30/90/90/60/21/20/40/30/70/40/10/210/150/20
DehydrationMetabolism and nutrition disorders0/30/90/90/60/21/21/40/30/70/40/10/210/150/20
HeadacheNervous system disorders0/30/90/90/61/20/20/40/30/70/40/10/210/150/20
Acute kidney injuryRenal and urinary disorders0/32/90/90/60/21/20/40/30/70/40/10/211/150/20
Pleural effusionRespiratory, thoracic and mediastinal disorders0/30/90/90/60/21/20/40/30/70/40/10/210/150/20
AstheniaGeneral disorders1/30/90/90/60/20/20/40/30/70/40/10/210/150/20
Non-cardiac chest painGeneral disorders0/30/90/90/60/20/20/41/30/70/40/10/210/150/20
Periprosthetic fractureInjury, poisoning and procedural complications1/30/90/90/60/20/20/40/30/70/40/10/210/150/20
Most frequent other events
Showing 10 of 234
Most frequent other events
EventAll Mono Esc 20 Q2WAll Mono Esc 80 Q2WAll Mono Esc 240 Q2WAll Mono Esc 800 Q2WCLL BMS-986016 240mgDLBCL BMS-986016 240mgiNHL BMS-986016 240mgHL BMS-986016 240mgAll Combo Esc 80/240 Q2WAll Combo Esc 160/240 Q2WAll Combo Esc 240/240 Q2WHL Naive BMS-986016 160mg + NivolumabDLBCL BMS-986016 160mg + NivolumabHL Post I/O BMS-986016 160mg + Nivolumab
Lymph node painBlood and lymphatic system disorders0/30/90/91/62/20/20/40/30/70/40/10/210/150/20
DiarrhoeaGastrointestinal disorders1/33/90/91/60/20/22/41/33/70/41/15/212/153/20
Gingival painGastrointestinal disorders0/30/90/90/60/20/20/40/30/70/41/10/210/150/20
StomatitisGastrointestinal disorders0/30/90/90/61/20/20/40/31/70/41/11/210/150/20
Mucosal inflammationGeneral disorders0/31/90/90/60/20/20/40/31/70/41/10/210/151/20
PainGeneral disorders0/31/90/90/60/20/20/40/31/70/41/10/210/150/20
Fungal infectionInfections and infestations0/30/90/90/60/20/20/40/30/70/41/10/210/150/20
Herpes zosterInfections and infestations1/30/90/90/60/20/20/40/30/70/41/11/210/150/20
Respiratory syncytial virus infectionInfections and infestations0/30/90/90/60/20/20/40/30/70/41/10/210/150/20
Upper respiratory tract infectionInfections and infestations1/32/92/90/61/20/20/41/32/72/41/16/211/154/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BMS-986016 20mgBMS-986016 800mgBMS-986016 80mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + NivolumabTotal
<=18 years00000000
Between 18 and 65 years23512314672
>=65 years1618401434
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986016 20mgBMS-986016 800mgBMS-986016 80mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + NivolumabTotal
Female0516402238
Male34514313868
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986016 20mgBMS-986016 800mgBMS-986016 80mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + NivolumabTotal
Hispanic or Latino00110024
Not Hispanic or Latino395197158102
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS-986016 20mgBMS-986016 800mgBMS-986016 80mgBMS-986016 240mgBMS-986016 80mg + NivolumabBMS-986016 240mg + NivolumabBMS-986016 160mg + NivolumabTotal
American Indian or Alaska Native00000000
Asian00000055
Native Hawaiian or Other Pacific Islander00000011
Black or African American11120049
White18516714583
More than one race00000000
Unknown or Not Reported10020058
08

Study locations

10 sites
  • Local Institution - 0007
    Baltimore, Maryland 21205, United States
  • Local Institution - 0004
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Local Institution - 0010
    Saint Louis, Missouri 63110, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Local Institution - 0002
    Portland, Oregon 97239, United States
  • Local Institution - 0006
    Houston, Texas 77030, United States
  • Local Institution - 0001
    Seattle, Washington 98109, United States
  • Local Institution - 0011
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0012
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Publications

  • El Halabi L, Adam J, Gravelle P, Marty V, Danu A, Lazarovici J, Ribrag V, Bosq J, Camara-Clayette V, Laurent C, Ghez D. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12. PubMed 33277223 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Feb 2022, 95 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's 95 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2014
First posted
Feb 13, 2014
StartActual
Mar 13, 2014
Primary completionActual
Feb 16, 2022
CompletionActual
Feb 16, 2022
Results first posted
Mar 24, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02061761
Responsible party
Sponsor
First posted
Feb 13, 2014
Start date
Mar 13, 2014
Primary completion
Feb 16, 2022
Completion
Feb 16, 2022
Results posted
Mar 24, 2023
Last update
Mar 24, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relatlimab

Start the discussion